BioCryst Provides Tremendous Option Value

  • The introduction of ORLADEYO has been a runaway success, and this is likely to continue with new payors and subscribers getting on board and international sales just around the corner.
  • With two pivotal trials for BCX9930 in preparation after a very successful P1 trial, the company has another potential blockbuster that can be useful in multiple diseases.
  • The company is well-financed and within a couple of years, it should generate the cash to finance more market introductions.
  • Investors have to keep in mind that before FDA approvals, nothing is given, but the shares contain tremendous option value on the possible success of further approvals.
  • Learn More »